Solutions
About Us
Insights
Careers
Contact us
Contact Us
Customer Support
Customer Support

Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease. Sands BE, Danese S, Chapman JC, Gurjar K, Grieve S, Thakur D, Griffith J, Joshi N, Kligys K, Dignass A. Inflamm Bowel Dis. 2025

Quantitative Bias Analysis for Single-Arm Trials With External Control Arms. Gupta A, Hsu G, Kent S, Duffield SJ, Merinopoulou E, Lockhart A, Arora P, Ray J, Wilkinson S, Scheuer N, Ramagopalan SV, Groenwold RHH, Popat S, Hernán MA. JAMA Netw Open. 2025

Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments. van Beekhuizen S, Che M, Monfort L, Hashim M, Azough A, Kubitz N, Griffin A, Price M. Pharmacoecon Open. 2025

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis. Huerta JL, Ta A, Vinand E, Torres GI, Wannaadisai W, Huang L. Hum Vaccin Immunother. 2025

A group concept mapping study of stakeholder perspectives on digital therapeutics economic value drivers. Sapanel Y, Cloutier LM, Tremblay G, Bourcet A, Koerber F, Lariviere D, Tadeo X, Ho D. NPJ Digit Med. 2025

Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study. Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, Chilelli A, Stoelzel M, Serikoff A, Spitzer SG. Adv Ther. 2025

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025

Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis. Barthélémy P, Musat MG, Moradian H, Kearney M. Future Oncol. 2025

Parent-of-origin effects in the life-course evolution of cardiometabolic traits. Wagh R, Hatem G, Andersson J, Kunte P, Bandyopadhyay S, Yajnik CS, Prasad RB. Diabetologia. 2025

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P. Clinicoecon Outcomes Res. 2025